- High
- —
- Open
- —
- VWAP
- —
- Vol
- —
- Mkt Cap
- 52.23M
- Low
- —
- Amount
- —
- EV/EBITDA, TTM
- —
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.
Analyst Ratings (1)
HC Wainwright & Co.
$45
2025-02-07
HC Wainwright & Co.
2025-02-07
Price Target
$45
Wolfe Research
$20
2025-02-04
Wolfe Research
2025-02-04
Price Target
$20
HC Wainwright & Co.
$45
2024-12-20
HC Wainwright & Co.
2024-12-20
Price Target
$45
HC Wainwright & Co.
$45
2024-11-25
HC Wainwright & Co.
2024-11-25
Price Target
$45
HC Wainwright & Co.
$45
2024-10-31
HC Wainwright & Co.
2024-10-31
Price Target
$45
Events Timeline
News
5.008-16BenzingaGreenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS
8.508-29NewsfilterARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split
2.008-29BenzingaWhy Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
- 8.008-26Newsfilter
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
- 8.508-23Newsfilter
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
ABIO FAQ — answered by Alphio AI
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).
1 analysts cover ABIO: 1 rate it Buy, 0 Hold and 0 Sell.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。